TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Price, Quote, News and Summary
NYSE:TAK - New York Stock Exchange, Inc. - US8740602052 - ADR
TAK Quote and Key Statistics
TAKEDA PHARMACEUTIC-SP ADR
NYSE:TAK (1/17/2025, 8:04:00 PM)
After market: 12.9 -0.02 (-0.15%)12.92
-0.13 (-1%)
TAK Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.38% | ||
| ROA | 1.99% | ||
| ROE | 4.19% | ||
| Debt/Equity | 0.64 |
TAK Performance and Technical Analysis
TAK Ownership and Analysts
TAK Latest News and Analysis
FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch
The U.S. Food and Drug Administration announced a ban on Red No. 3, an artificial food coloring linked to cancer in animal studies, effective Jan. 15, 2027.
Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency
Takeda's HYQVIA receives approval in Japan for treating immunodeficiencies, offering a more convenient, less frequent subcutaneous infusion option.
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
About TAK
Company Profile
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 49,281 full-time employees. The firm is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The firm's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The firm is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Company Info
TAKEDA PHARMACEUTIC-SP ADR
4F, 2-1-1, Nihombashihon-cho
Chuo-Ku TOKYO-TO 103-8668 JP
CEO: Christophe Weber
Employees: 49281
Company Website: https://www.takeda.com/
Investor Relations: https://www.takeda.com/investors
Phone: 81332782111
TAK Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 71.36 | 688.94B | ||
| JNJ | JOHNSON & JOHNSON | 14.36 | 353.99B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.77 | 349.49B | ||
| MRK | MERCK & CO. INC. | 16.46 | 247.70B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.48 | 206.53B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.07 | 194.99B | ||
| PFE | PFIZER INC | 10.19 | 149.04B | ||
| SNY | SANOFI-ADR | 12.29 | 127.21B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.11 | 114.17B | ||
| ZTS | ZOETIS INC | 28.8 | 74.84B | ||
| GSK | GSK PLC-SPON ADR | 8.21 | 68.21B | ||
| TEVA | TEVA PHARMACEUTICAL-SP ADR | 7.88 | 24.83B |